Search
alefacept (Amevive)
Indications:
- psoriasis
- may preserve beta-cell function in patients with new-onset type 1 diabetes [3]
Contraindications:
-> HIV [2]
Dosage:
- 15 mg IM weekly
Adverse effects:
- reduces CD4 count [2]
Mechanism of action:
- inhibits T-cells
- targets CD2 present on cell surface of memory T-cells
Notes:
- Alefacept was withdrawn from the market in 2011 because of "business needs"
Specific
Alefacept Parenteral
General
immunosuppressive agent
recombinant protein; chimer
References
- Prescriber's Letter 10(12):69 2003
- FDA Medwatch
http://www.fda.gov/medwatch/safety/2005/safety05.htm#Amevive
- Physician's First Watch, September 23, 2013
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Rigby MR et al
Targeting of memory T cells with alefacept in new-onset type 1
diabetes (T1DAL study): 12 month results of a randomised,
double-blind, placebo-controlled phase 2 trial.
The Lancet Diabetes & Endocrinology, September 23, 2013
PMID: 24622414
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70111-6/abstract
- Herold KC
Restoring immune balance in type 1 diabetes.
The Lancet Diabetes & Endocrinology, September 23, 2013
PMID: 24622404
http://www.thelancet.com/journals/landia/article/PIIS2213-8587%2813%2970123-2/fulltext
- Voluntary US Market Discontinuation of Amevive (alefacept)
Astellas Pharma US, Inc. December 15, 2011
http://www.amevive.com/Physician%20letter.pdf